Tech Review

Future challenges in biomanufacturing

22.08.2011

Outsourcing is one of the biggest global trends in the biopharmaceutical industry. It is taking more and more specific know-how to master the challenges posed by manufacturing of biologics, which include rising price and cost pressures, the need for high flexibility, and the ever-shifting (and in most cases

growing) regulatory requirements for biomanufacturing. This article will give you an overview of how a contract manufacturing organisation (CMO) with many years of experience in manufacturing several classes of bio­pharmaceuticals is positioning itself to face these challenges.

In the maturing biopharmaceutical industry today, there is increasing competition to innovative pipelines from me-too products, biobetters and biosimilars. The pressure on the cost of goods (COG) is therefore increasing. And to reduce COG, each manufacturing facility needs to meet the specific requirements for a new project regarding the technical instrumentation even before the project enters its initial stages. This will reduce investment and later depreciation, which impact negatively on costs. At the same time, it is important to be able to maintain as much flexibility as possible in order to comply with upcoming regulatory requirements. Thus CMOs need to invest constantly in the development and establishment of new manufacturing technologies and the necessary equipment.

Implementation of new

process technologies

At Richter-Helm, the investment in new technology does not focus only on adding new (greater) manufacturing scales, although this is often a first reaction to COG pressure. Many firms consider

decreasing costs by increasing scale.
But a good alternative to simple scale-up is the implementation of new process technologies that can achieve higher yields, while at the same time improving quality or process robustness – at least for certain processing steps. Over the past few years, the biomanufacturing industry has made substantial improvements in expression and fermentation technologies. In terms of microbial production, innovative E. coli expression systems combined with high density fermentation regimes can lead to yields up to 20g of the target protein per litre of fermentation broth – as was recently accomplished by Richter-Helm for a fusion protein process[1].
In addition to high product yields, in many cases it is also important to find the appropriate expression system for high-quality products that show no or only low expression rates in E. coli. In these cases, the use of other bacterial expression hosts such as Bacillus or Pseudomonas strains can help. Pichia pastoris technology is another option for dealing with even more complex proteins such as enzymes or antibody fragments. A multipurpose facility for manufacturing bio­pharmaceuticals therefore needs to be equipped to take advantage of all these expression systems in order to be able to reduce upfront investment costs from the outset.
New expression systems lead to high primary product yields, and these need to be dealt with in purification processes. Thus optimisation of the downstream processes is also necessary. A recent study showed that the implementation of EBA technology can reduce total process cost by up to 56%[2]. Other new purification technologies that can be implemented include multi­column counter current solvent gradient purification (MCSGP), which reduces the loss of product in chromatography steps.
An ongoing trend in biopharmaceutical product development is the covalent modification of proteins by chemical or enzymatic cross linking (e.g. PEGylation, HESylation, Polyasialation) to increase the half-life of those products in humans. These technologies therefore need to be accessible in a multipurpose facility as well.

Expert project management

Of course, all of the technologies mentioned above also need to be scalable. For a CMO to offer customers the option of going from bench to market with a single manufacturer, it is important to offer more than one scale. For instance, at Richter-Helm three different manufacturing scales are available (lab, pilot, large) to implement each project at the best matching scale while limiting costs for large equipment or a higher number of batches (Fig. 1).
But a CMO does not only need sufficient technical capabilities to serve the future needs of its customers. Professional project execution is also a major success factor. It is extremely important for a CMO to be prepared for the fact that different customers have different requirements, as they range from small start-ups to big pharma. The project approach, for example regarding the regulatory consultancy required, will be extremely dependent on the customer’s situation (Fig. 2). Project management that ensures close collaboration and communication between all parties is becoming increasingly important, driven by the trend towards long-lasting partnerships and strategic alliances between developers and manufacturers.D


References
[1] Kaiser et al., Steigerung von Qualität und Ausbeute in der Wirkstoffproduktion; Laborwelt 11 (3), 18-22, 2010
[2] May, Pohlmeyer; Improving Process Economy with Expanded-Bed Adsorption Technology, BioProcess International, January 2011

Contact
Dr. Kai Pohlmeyer
Dr.-Ing. Philipp Göpel
Richter-Helm BioTec GmbH & Co. KG
Nordkanalstrasse 28
20097 Hamburg, Germany
Tel.: +49 40 2375-0
k.pohlmeyer@richter-helm-biotec.eu
p.goepel@richter-helm-biotec.eu
www.richter-helm-biotec.eu

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1982

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/future-challenges-in-biomanufacturing.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper